Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Dir. Changes/Trading Update

29 Mar 2006 07:01

Marchpole Holdings PLC29 March 2006 Marchpole Holdings plc Directorate Changes and Trading Update The Board of Marchpole Holdings plc ("Marchpole" or "the Group"), the fastgrowing fashion brand management group, announces that following the recentcompletion of its acquisition of Moda America LLC, it has made the followingstrategic changes to reflect its new multi brand international structure. Allchanges take place with immediate effect. - Michael Morris, currently Executive Director and founder of Marchpole with more than 30 years' experience within the fashion clothing industry, is appointed Executive Deputy Chairman and will assume overall senior executive responsibilities - John Harrison, director and full-time Acting Finance Director since October 2005, is appointed executive Group Finance Director on a permanent basis - Chief executive Greg Tufnell has resigned to pursue other business interests - Deloitte is appointed as Group worldwide auditors - Bell Pottinger Corporate & Financial is appointed as global Group Financial PR adviser - Trading continues in line with market expectations and the Board views the outlook for the Group with confidence Non-Executive Chairman Christopher Phillips commented that the changes announcedtoday reflect the fundamental strategic developments that have taken placewithin the Group over the last two years. Now with significant operations in theUK, mainland Europe, Asia and the USA for a wide range of fashion brands,Marchpole has evolved from being a single brand, single country business to adiversified multi-brand international business with strong growth potential. Mr Phillips, Non-Executive Chairman, said: "I am pleased to state that tradingis in line with market expectations and the Board looks forward to acceleratinggrowth across all of our operations. "The acquisition of Moda America - with a turnover of US$20 million in the yearto end-2005 - is a highly significant development as it offers a uniqueopportunity for Marchpole to exploit its proven brand management skills toexpand the business into the world's largest market, the USA. "I am confident that the restructuring of the Board and management provides fora robust structure which will serve the Group well for the next stage of itsdevelopment." - ends - For further information David Rydell/Emma Kent/Alexandra Walton Bell Pottinger Corporate & Financial 0207 861 3232 Notes to Editors - Marchpole Holdings plc ("Marchpole") is an international brand management group that designs, produces and sells clothing and accessories for six world class fashion labels. It operates in all of the world's main markets - UK, mainland Europe, Asia and the USA - Its respected brands include YSL, Boateng, Emanuel Ungaro, Ungaro, Jean-Charles de Castelbajac ("JCC") and Jean-Charles de Castelbajac/Rossignol - Incorporated in 1973, Marchpole listed on the London Stock Exchange in 1997 and has the ticker symbol MPH - Marchpole is renowned for its integrated approach to brand management, taking a brand from concept to design studio to the customer interface. It is not a clothing manufacturer - The Group has grown considerably in the past 3 years, from a licensee with one core licence (YSL menswear) - to today's international business that manages its brands across a multitude of clothing lines and accessories - Marchpole's most recent acquisition (effective January 2006) of Moda America LLC - the US licensee for leading designer Emanuel Ungaro - brings further growth opportunities in the UK and America and strengthens the Group's relationship with Emanuel Ungaro - The Moda acquisition also allows the Group to launch Emanuel Ungaro, already established by Marchpole in Europe and Asia, into the US, Canada and South America. In addition, the acquisition allows the Group to re-launch JCC into America with effect from Autumn/Winter 2006 - Marchpole will launch the diffusion Ungaro homme collection in the UK from Spring/Summer 2007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
11th Feb 20197:00 amRNSBoard Change
25th Jan 201911:10 amRNSPublication of F-4
18th Jan 20197:00 amRNSNew Deferred Bonus Plan
15th Jan 20197:00 amRNSBGS-649 Phase 2b data to be Presented at ENDO 2019
27th Dec 201810:02 amRNSDirector/PDMR Shareholding
24th Dec 20187:00 amRNSDirector/PDMR Shareholding
18th Dec 20187:00 amRNSPositive results from safety extension study
17th Dec 20186:25 pmRNSPositive results from safety extension study
17th Dec 20183:44 pmRNSAIM Rule 17 Disclosure Statement
10th Dec 20187:00 amRNSPresentation at BMO Healthcare Conference
5th Dec 20181:09 pmRNSProposed combination of Mereo and OncoMed
26th Nov 20187:00 amRNSIssue of Warrants
5th Nov 20187:00 amRNSFirst patient dosed in Phase 2 study
31st Oct 20183:37 pmRNSTotal Voting Rights
15th Oct 20187:00 amRNSCompletion of Patient Enrolment in Phase 2b study
1st Oct 201810:00 amRNSRevised Credit Facility and Issue of Warrants
3rd Sep 20187:00 amRNSBlock Listing Application
31st Aug 20186:25 pmRNSCorrection to Issued Share Capital
8th Aug 20187:00 amRNSMereo BioPharma Interim Results 2018
23rd Jul 20187:00 amRNSNotice of Interim Results
23rd Jul 20187:00 amRNSExercise of Options
21st Jun 201812:52 pmRNSResult of Annual General Meeting
29th May 20187:00 amRNSSuccessful Completion of PrimaryBid Offer
25th May 20184:31 pmRNSPrimaryBid.com Offer
22nd May 20187:00 amRNSNotice of AGM
27th Apr 20187:00 amRNSGrant of Options
26th Apr 20187:00 amRNSUpdate on Offering & Application to List on Nasdaq
9th Apr 201811:34 amRNSOffering and Application to List on Nasdaq
6th Apr 20181:03 pmRNSResult of General Meeting
3rd Apr 20187:00 amRNSPublication of Annual Report
26th Mar 20187:00 amRNSMereo BioPharma Files for Proposed Global Offering
23rd Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSPUBLICATION OF NOTICE OF GENERAL MEETING
20th Mar 20187:00 amRNSMereo selected for oral presentation at ATS 2018
19th Mar 20187:00 amRNSMereo: Positive Top-Line Results for BGS-649
26th Feb 20187:00 amRNSMereo BioPharma Appoints Wills Hughes-Wilson
2nd Jan 20187:00 amRNS£10m credit facility drawdown & issue of warrants
18th Dec 20177:00 amRNSMereo Plans to Conduct Registered IPO in the US
13th Dec 20177:00 amRNSMereo BioPharma: Business Update
11th Dec 20177:00 amRNSPositive results from Phase 2 trial with BCT-197
13th Nov 20177:00 amRNSBPS-804 receives PRIME designation
6th Nov 201712:19 pmRNSHolding(s) in Company
30th Oct 20177:00 amRNSMereo announces agreement with AstraZeneca
18th Sep 20177:00 amRNSMereo to Present at Cantor Healthcare Conference
5th Sep 20177:00 amRNSUpdate on BGS-649 Phase 2b Study
22nd Aug 20179:17 amRNSIssue of Warrants
8th Aug 20177:12 amRNSInterim Results
3rd Jul 20177:00 amRNSNotice of Results
27th Jun 201711:23 amRNSResult of AGM
15th May 20177:00 amRNSUpdate on acumapimod Phase 2 Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.